Millennium licenses Xenova's oncology compounds; terminated
Executive Summary
Millennium Pharmaceuticals has licensed exclusive North American marketing rights to Xenova's (focuses on cancer drugs) oncology compounds including Phase I XR11576 and two preclinical drugs, XR5944 and XR11612. The drugs dually inhibit topoisomerases I and II to treat solid tumors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice